Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 32 Records) |
| Query Trace: Adenocarcinoma and MTOR[original query] |
|---|
| A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese population. PloS one 2013 8 (3): e60080. Xu Ming, Tao Guoquan, Kang Meiyun, Gao Yan, Zhu Haixia, Gong Weida, Wang Meilin, Wu Dongmei, Zhang Zhengdong, Zhao Qingho |
| Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Molecular carcinogenesis 2013 Nov 52 Suppl 1 E70-9. He Jing, Wang Meng-Yun, Qiu Li-Xin, Zhu Mei-Ling, Shi Ting-Yan, Zhou Xiao-Yan, Sun Meng-Hong, Yang Ya-Jun, Wang Jiu-Cun, Jin Li, Wang Ya-Nong, Li Jin, Yu Hong-Ping, Wei Qing- |
| TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. Journal of translational medicine 2014 12 (1): 255. Tornesello Maria Lina, Annunziata Clorinda, Buonaguro Luigi, Losito Simona, Greggi Stefano, Buonaguro Franco |
| Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer. Annals of surgical oncology 2014 Dec 21 Suppl 4 S634-9. Lee Soo Jung, Kang Byung Woog, Chae Yee Soo, Kim Hye Jin, Park Su Yeon, Park Jun Seok, Choi Gyu Seog, Jeon Hyo-Sung, Lee Won Kee, Kim Jong Gwa |
| PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PloS one 2014 9 (2): e88291. Wang Lei, Hu Haichuan, Pan Yunjian, Wang Rui, Li Yuan, Shen Lei, Yu Yongfu, Li Hang, Cai Deng, Sun Yihua, Chen Haiqu |
| Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget 2014 Nov 5 (22): 11168-79. Hou Ming-Mo, Liu Xiaochun, Wheler Jennifer, Naing Aung, Hong David, Coleman Robert L, Tsimberidou Apostolia, Janku Filip, Zinner Ralph, Lu Karen, Kurzrock Razelle, Fu Siqi |
| Genetic variations in the mTOR gene contribute toward gastric adenocarcinoma susceptibility in an Eastern Chinese population. Pharmacogenetics and genomics 2015 Aug . Wang Meng-Yun, Li Qiao-Xin, He Jing, Qiu Li-Xin, Wang Ya-Nong, Li Jin, Sun Meng-Hong, Wang Xiao-Feng, Yang Ya-Jun, Wang Jiu-Cun, Jin Li, Wei Qing- |
| Atypical Polypoid Adenomyoma of the Uterus: An Immunohistochemical and Molecular Study of 21 Cases. The American journal of surgical pathology 2015 Aug 39 (8): 1148-55. N?mejcová Kristýna, Kenny Sarah L, Laco Jan, Škapa Petr, Stan?k Libor, Zikán Michal, Kleiblová Petra, McCluggage W Glenn, Dundr Pav |
| Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). Oncotarget 2016 Apr . Lim Sun Min, Kim Hye Ryun, Cho Eun Kyung, Min Young Joo, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil, Cho Byoung Chul, Lee Ji-Hyun, Jeong Hye Cheol, Kim Eun Kyung, Kim Joo-Ha |
| Pulmonary Neoplasms in Patients with Birt-Hogg-Dubé Syndrome: Histopathological Features and Genetic and Somatic Events. PloS one 2016 11 (3): e0151476. Furuya Mitsuko, Tanaka Reiko, Okudela Koji, Nakamura Satoko, Yoshioka Hiromu, Tsuzuki Toyonori, Shibuya Ryo, Yatera Kazuhiro, Shirasaki Hiroki, Sudo Yoshiko, Kimura Naoko, Yamada Kazuaki, Uematsu Shugo, Kunimura Toshiaki, Kato Ikuma, Nakatani Yuk |
| Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2017 8 12 (12): 1766-1778. Zhong Jia, Li Lei, Wang Zhijie, Bai Hua, Gai Fei, Duan Jianchun, Zhao Jun, Zhuo Minglei, Wang Yuyan, Wang Shuhang, Zang Wanchun, Wu Meina, An Tongtong, Rao Guanhua, Zhu Guanshan, Wang J |
| Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer cell 2017 8 32 (2): 185-203.e13. , |
| Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. Current oncology (Toronto, Ont.) 2017 1 23 (6): e571-e575. Sheffield B S, Tessier-Cloutier B, Li-Chang H, Shen Y, Pleasance E, Kasaian K, Li Y, Jones S J M, Lim H J, Renouf D J, Huntsman D G, Yip S, Laskin J, Marra M, Schaeffer D |
| Landscape of somatic mutations in gastric cancer assessed using next-generation sequencing analysis. Oncology letters 2018 Oct 16 (4): 4863-4870. Pan Xuan, Ji Xiaozhi, Zhang Renmin, Zhou Zhaofei, Zhong Yuejiao, Peng Wei, Sun Ning, Xu Xinyu, Xia Lei, Li Pansong, Lu Jianwei, Tu Ji |
| PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis. Translational oncology 2019 Dec 13 (2): 157-164. Essakly Ahlem, Loeser Heike, Kraemer Max, Alakus Hakan, Chon Seung-Hun, Zander Thomas, Buettner Reinhard, Hillmer Axel M, Bruns Christiane J, Schroeder Wolfgang, Gebauer Florian, Quaas Alexand |
| Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design. Clinical lung cancer 2020 Oct . Riess Jonathan W, Frankel Paul, Shackelford David, Dunphy Mark, Badawi Ramsey D, Nardo Lorenzo, Cherry Simon R, Lanza Ian, Reid Joel, Gonsalves Wilson I, Kunos Charles, Gandara David R, Lara Primo N, Newman Edward, Paik Paul |
| Genetic characteristics and prognostic implications of m1A regulators in pancreatic cancer. Bioscience reports 2021 Apr 41 (4): . Zheng Qingyuan, Yu Xiao, Zhang Qiyao, He Yuting, Guo Wenz |
| Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumors. Journal for immunotherapy of cancer 2021 10 9 (10): . Hwang Hee Sang, Kim Deokhoon, Choi Je |
| Next-generation Sequencing Reveals Age-dependent Genetic Underpinnings in Lung adenocarcinoma. Journal of Cancer 2022 4 13 (5): 1565-1572. Wu Xiaonan, Zhao Jun, Yang Ling, Nie Xin, Wang Zheng, Zhang Ping, Li Chao, Hu Xueqing, Tang Min, Yi Yuting, Du Xinhua, Xia Xuefeng, Guan Yanfang, Yu Zicheng, Gu Wenguang, Quan Xiangming, Li Lin, Shi Ho |
| Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma. BMC medicine 2022 4 20 (1): 133. Wang Zhenghang, Wang Xinyu, Xu Yu, Li Jian, Zhang Xiaotian, Peng Zhi, Hu Yajie, Zhao Xinya, Dong Kun, Zhang Bei, Gao Chan, Zhao Xiaochen, Chen Hui, Cai Jinping, Bai Yuezong, Sun Yu, Shen L |
| Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer. Thoracic cancer 2022 Oct . Choi Sun Ha, Do Sook Kyung, Lee Shin Yup, Choi Jin Eun, Kang Hyo-Gyoung, Hong Mi Jeong, Lee Jang Hyuck, Lee Won Kee, Jeong Ji Yun, Shin Kyung Min, Do Young Woo, Lee Eung Bae, Park Ji Eun, Lee Yong Hoon, Seo Hyewon, Yoo Seung Soo, Lee Jaehee, Cha Seung Ick, Kim Chang Ho, Park Jae Yo |
| Clear Cell Adenocarcinoma of Urethra: Clinical and Pathologic Implications and Characterization of Molecular Aberrations. Cancer research and treatment 2023 9 . Boram Song, Seok Hyun Lee, Jeong Hwan Park, Kyung Chul Mo |
| Comparison of gene mutation profile in different lung adenocarcinoma subtypes by targeted next-generation sequencing. Medical oncology (Northwood, London, England) 2023 11 40 (12): 349. Shaowen Zhang, Ping Dong, Zongwei Pan, Qian Chen, Junqi Zhu, Zhangfan M |
| A Comprehensive Analysis of the Effects of Key Mitophagy Genes on the Progression and Prognosis of Lung Adenocarcinoma. Cancers 2023 1 15 (1): . Dai Dongjun, Liu Lihong, Guo Yinglu, Shui Yongjie, Wei Qich |
| [Gene mutation characteristics of clinical stage ?A lung adenocarcinoma and their relations with patients' long-term prognosis]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2024 8 46 (8): 755-763. L Zhang, M W Liu, L Li, S Zhao, L L Wu, Z H Yin, M Li, Y N Gao, N |
| Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings of the National Academy of Sciences of the United States of America 2024 4 121 (17): e2321898121. Stefania Bellone, Kyungjo Jeong, Mari Kyllesø Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman, Levent Mutlu, Cem Demirkiran, Tobias Max Philipp Hartwich, Yang Yang-Hartwich, Margherita Zipponi, Natalia Buza, Pei Hui, Francesco Raspagliesi, Salvatore Lopez, Biagio Paolini, Massimo Milione, Emanuele Perrone, Giovanni Scambia, Gary Altwerger, Antonella Ravaggi, Eliana Bignotti, Gloria S Huang, Vaagn Andikyan, Mitchell Clark, Elena Ratner, Masoud Azodi, Peter E Schwartz, Charles M Quick, Roberto Angioli, Corrado Terranova, Samir Zaidi, Shuvro Nandi, Ludmil B Alexandrov, Eric R Siegel, Jungmin Choi, Joseph Schlessinger, Alessandro D Sant |
| Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example. Molecular biomedicine 2024 4 5 (1): 13. Shutao Zheng, Shuo He, Yan Liang, Yiyi Tan, Qing Liu, Tao Liu, Xiaomei |
| Erratum for the research article "The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study" by Huang et al. Clinical and translational medicine 2024 12 15 (1): e70158. Lei Huang, Hui Yang, Kaidi Chen, Jing Yuan, Jie Li, Guanghai Dai, Mancang Gu, Yan S |
| Race- associated molecular differences in uterine serous carcinoma. Frontiers in oncology 2024 10 14 1445128. Olivia D Lara, Hannah Karpel, Steven Friedman, Kari E Hacker, Bhavana Pothu |
| Identification of ferroptosis-related signature predicting prognosis and therapeutic responses in pancreatic cancer. Scientific reports 2025 1 15 (1): 75. Ting Ting Chung, Zanyue Piao, Seung Jin L |
- Page last reviewed:Feb 1, 2024
- Content source: